Combined use of Clauss and prothrombin time‐derived methods for determining fibrinogen concentrations: Screening for congenital dysfibrinogenemia

Background In this study, the significance of fibrinogen concentration assessed by a combination of Clauss and prothrombin time (PT)‐derived methods for screening for congenital dysfibrinogenemia were investigated, and the screening efficiency of fibrinogen PT‐derived/Clauss ratio on congenital dysfibrinogenemia was analyzed. Methods We compared fibrinogen concentrations determined by the Clauss, PT‐derived, and enzyme‐linked immunosorbent assay (ELISA) methods in 73 patients with congenital dysfibrinogenemia and 81 normal controls. Receiver operating characteristic (ROC) curves were utilized to evaluate the efficacy of fibrinogen PT‐derived/Clauss ratio in screening for congenital dysfibrinogenemia. Results Fibrinogen concentrations determined by the Clauss method were dramatically lower than by the PT‐derived method and ELISA, and correlated poorly with the latter two methods in patients with congenital dysfibrinogenemia. Fibrinogen concentrations in normal controls were slightly lower according to the Clauss method than to the PT‐derived method and ELISA; however, each method yielded results within the normal range and the correlation was good. The area under the ROC curve of fibrinogen PT‐derived/Clauss ratio for diagnosis of congenital dysfibrinogenemia was 1 with a standard error of 0, 95% confidence interval of 0.976‐1.00, and optimal critical diagnosis point of 1.43. When fibrinogen PT‐derived/Clauss ratio was >1.43, the sensitivity and specificity for diagnosis of congenital dysfibrinogenemia were both 100%. Conclusions The combined use of Clauss and PT‐derived methods for determining fibrinogen concentrations improves the efficiency of screening for congenital dysfibrinogenemia, as the fibrinogen PT‐derived/Clauss ratio has high sensitivity and specificity in diagnosis of congenital dysfibrinogenemia. This ratio could serve an important screening tool for this disease.